Tirzepatide
Dual GIP/GLP-1 receptor agonist
A dual GIP/GLP-1 receptor agonist of significant interest in metabolic peptide research.
Also referenced as: GLP-T
Overview
Developed by Eli Lilly as the first approved dual agonist targeting both the GIP and GLP-1 receptors. It received first FDA approval in 2022.
At a glance
What Tirzepatide does
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single 39-amino-acid synthetic peptide, based on the GIP sequence, engineered to activate both incretin receptors and fitted with a C20 fatty-diacid for a ~5-day half-life and once-weekly use. Its defining feature is the added GIP-receptor activity layered on top of GLP-1 agonism. Through the GLP-1 arm it drives glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite reduction; the GIP arm further potentiates nutrient-stimulated insulin release and is thought to improve adipose-tissue insulin sensitivity and lipid handling, and may improve nausea tolerability relative to GLP-1 alone. The molecule is biased toward the GIP receptor in its binding profile.
Clinically this dual mechanism has produced some of the largest metabolic effects of any compound in the class. In the SURPASS type-2-diabetes trials, tirzepatide lowered HbA1c by roughly 2.0-2.6 percentage points and outperformed semaglutide 1 mg head-to-head (SURPASS-2). In the SURMOUNT obesity program, the top 15 mg weekly dose produced mean body-weight reductions in the range of ~21-22% over 72 weeks in people without diabetes — among the highest yet reported for a pharmacologic agent. Downstream effects observed include large reductions in fasting and post-meal glucose, improved lipid profiles, lower blood pressure, and reductions in liver fat; SURMOUNT-OSA showed improvement in obstructive sleep apnea. Evidence is robust human-clinical data, and tirzepatide is regulator-approved for both type 2 diabetes and chronic weight management.
Effects reported in research
- Dual activation of GIP and GLP-1 receptors, potentiating glucose-dependent insulin secretion more than GLP-1 mono-agonism (human clinical).
- HbA1c reductions of ~2.0-2.6% in the SURPASS type-2-diabetes trials, exceeding semaglutide 1 mg head-to-head in SURPASS-2 (human clinical).
- ~21-22% mean body-weight reduction at 15 mg weekly over 72 weeks in the SURMOUNT-1 obesity trial (human clinical).
- Suppressed glucagon and slowed gastric emptying, flattening post-prandial glucose excursions (human clinical).
- Reduced central appetite and caloric intake via GLP-1 satiety pathways (human clinical).
- Reduced liver fat content and improved markers of metabolic-associated steatohepatitis in imaging sub-studies (human clinical).
- Improved lipid profile and reduced blood pressure alongside weight loss (human clinical).
- Improved obstructive sleep apnea severity (apnea-hypopnea index) in the SURMOUNT-OSA trial (human clinical).
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Combined agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake. It carries a C20 fatty-diacid moiety enabling albumin binding and a prolonged half-life supporting once-weekly administration.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Tirzepatide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- First-in-class agonist engineered to activate two incretin receptors (GIP and GLP-1) with a single molecule
- Based on the GIP peptide sequence and modified to also engage the GLP-1 receptor
- Contains a C20 fatty-diacid side chain that supports albumin binding and once-weekly subcutaneous dosing
- Marketed under distinct brand names for diabetes (Mounjaro) versus weight management (Zepbound)
- Studied across a broad clinical trial program (SURPASS for diabetes, SURMOUNT for weight)
- Its dual-receptor action is a key structural and pharmacological difference from single GLP-1 agonists
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Tirzepatide is a research compound.
In the human clinical literature tirzepatide is given once weekly with a stepwise escalation. These are reference figures describing published research/protocols, not dosing guidance for humans.
- Reported weekly escalation: 2.5 mg -> 5 mg -> 7.5 mg -> 10 mg -> 12.5 mg -> 15 mg once weekly (each step ~4 weeks)
- Common maintenance references in the literature: 5-15 mg once weekly
Half-life ~5 days drives the once-weekly schedule. Reference figures for research context only.
How it compares
Tirzepatide differs from semaglutide and other single GLP-1 agonists by simultaneously engaging the GIP receptor, a mechanism proposed to contribute to its metabolic effects.
Commonly studied alongside
Compounds frequently researched together with Tirzepatide in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Tirzepatide sits in the GLP-1 Family area of the PeptiDex library.
- Entry type: Research compound reference
- Browse the full library →
- Glossary of terms →
Where researchers source Tirzepatide
For researchers studying Tirzepatide, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is tirzepatide and how is its mechanism different from a GLP-1 mono-agonist?
Tirzepatide is a dual agonist that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors from a single synthetic peptide backbone with a C20 fatty-diacid for half-life extension. The added GIP activity is the key distinction from GLP-1-only agonists like semaglutide. It is studied in models of glucose handling, appetite, and body-weight change.
What is tirzepatide's half-life and what does it imply for study design?
Tirzepatide has a reported half-life of about 5 days (~117 hours), supporting once-weekly administration in the literature. Steady state is generally reached after about 4 weeks at a given dose, so protocols include a multi-week escalation before maintenance-phase readouts. The multi-day half-life also means a washout of several weeks after discontinuation.
How is tirzepatide dose-escalated in research protocols?
Published protocols escalate weekly from 2.5 mg upward through 5, 7.5, 10, 12.5 and up to 15 mg once weekly, with each step commonly held about 4 weeks. As with other incretin agonists, escalation is used to limit gastrointestinal tolerability issues. These are reference figures for research context only, not human dosing guidance.
Why is tirzepatide sometimes called a 'twincretin'?
The nickname reflects its simultaneous agonism at the two incretin receptors, GIP and GLP-1. This dual-incretin activity is the mechanistic feature researchers study when comparing it to single-pathway GLP-1 agonists. It is distinct from the GLP-1/glucagon and triple-agonist classes.
Is tirzepatide an approved drug?
Yes — tirzepatide is an approved once-weekly injectable for glycemic and weight-management indications in humans. In a research catalog it is treated only as a reference research chemical, and research-grade material is not for human use and is not a substitute for the approved product.
What purity and documentation should be expected for research-grade tirzepatide?
A third-party COA with HPLC purity (commonly greater than or equal to 98%) and mass-spec identity confirmation is the standard reference documentation. Lyophilized peptide should be stored cold and reconstituted with bacteriostatic water for research handling, protected from light and freeze-thaw cycles.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.